About HER-2 Positive Breast Cancer
Breast cancer is characterized by uncontrolled growth of cancerous cells in the breast. It occurs in both males and females, however, the incidence of breast cancer in males is rare. Histologically, breast cancer can be classified into ductal carcinoma, lobular carcinoma, nipple cancer, and other undifferentiated carcinoma. Breast cancer is the second most common form of cancer in women. HER-2 is a protein that affects the growth of malignant cells and is usually found on the surface of normal breast cells. Sometimes, a large number of HER-2 receptors are found on the surface of breast cancer cells. These HER-2 receptors are responsible for stimulating the growth and division of malignant cancerous cells. This condition is therefore known as HER-2 positive breast cancer. HER-2 positive breast cancers have a tendency to spread and metastasize more rapidly than HER-2 negative breast cancers. HER-2 positive breast cancer is more prevalent in females than males. In 2012, GLOBOCAN reported that breast cancer accounted for 11.9 percent of the total number of cancer cases and led to 522,000 deaths worldwide. HER-2 positive breast cancer accounts for almost 25 percent of all types of breast cancer.
TechNavio's analysts forecast the HER-2 Positive Breast Cancer market in US to grow at a CAGR of 12.65 percent over the period 2014-2019.
Covered in this Report
This report covers the present scenario and the growth prospects of the HER-2 Positive Breast Cancer market in the US for the period 2015-2019. To calculate the market size, the report considers revenue generated through the sales of targeted therapeutics and chemotherapeutics used in the management of HER-2 positive breast cancer patients.
The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the HER-2 Positive Breast Cancer market in the US. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market.
TechNavio's report, HER-2 Positive Breast Cancer Market in US 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape of the HER-2 Positive Breast Cancer market in the US and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Vendors
• Celgene
• F. Hoffmann-La Roche
• GlaxoSmithKline
• Novartis
• Sanofi
Other Prominent Vendors
• Bristol-Myers Squibb
• DARA BioSciences
• Eisai
• Hospira
• Pfizer
• ProStrakan
• Sun Pharmaceutical Industries
• Teva Pharmaceutical
Market Driver
• Increase in Population of Breast Cancer Patients
• For a full, detailed list, view our report
Market Challenge
• Poor Diagnosis and Screening
• For a full, detailed list, view our report
Market Trend
• Increase in Awareness
• For a full, detailed list, view our report
Key Questions Answered in this Report
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Disease Overview
06.1 Understanding the Disease
06.2 Pathophysiology
06.3 Epidemiology
06.4 Diagnosis
06.4.1 IHC
06.4.2 FISH
06.4.3 SPoT-Light HER-2 CISH Test (Subtraction Probe Technology Chromogenic In Situ Hybridization)
06.4.4 Inform HER-2 Dual ISH Test (Inform Dual In Situ Hybridization)
06.5 Management
06.5.1 Surgery
06.5.2 Radiotherapy
06.5.3 Chemotherapy
06.5.4 Targeted Therapy
06.5.5 Hormonal Therapy
06.6 Economic Burden
07. Market Landscape
07.1 Market Overview
07.2 Market Size and Forecast
07.3 Five Forces Analysis
08. Market Segmentation by Type of Therapy
08.1 Chemotherapy
08.1.1 Alkylating Agents
08.1.2 Antimetabolites
08.1.3 Cytotoxic Antibiotics
08.1.4 Taxanes
08.2 Targeted Therapy
08.3 Hormone Therapy
09. 9 Market Segmentation by Molecule Type
09.1 Biologics
09.2 Small Molecules
10 Market Segmentation by Route of Administration
10.1 Oral
10.2 Parenteral
11 Buying Criteria
12 Market Growth Drivers
13 Drivers and their Impact
14 Market Challenges
15 Impact of Drivers and Challenges
16 Market Trends
17 Trends and their Impact
18 Vendor Landscape
18.1 Competitive Scenario
18.1.1 Key News
18.1.2 Mergers and Acquisitions
18.2 Market Share Analysis 2014
18.2.1 Competitive Assessment of the Top Drugs
18.2.2 Celgene
18.2.3 F. Hoffmann-La Roche
18.2.4 GlaxoSmithKline
18.2.5 Novartis
18.2.6 Sanofi
18.3 Other Prominent Vendors
19 Key Vendor Analysis
19.1 Celgene
19.1.1 Key Facts
19.1.2 Business Overview
19.1.3 Business Strategy
19.1.4 Business Segmentation by Revenue
19.1.5 Sales by Geography
19.1.6 Key Information
19.1.7 SWOT Analysis
19.2 F. Hoffmann-La Roche
19.2.1 Key Facts
19.2.2 Business Overview
19.2.3 Business Segmentation
19.2.4 Business Segmentation by Revenue 2012 and 2013
19.2.5 Sales by Geography
19.2.6 Business Strategy
19.2.7 Key Information
19.2.8 SWOT Analysis
19.3 GlaxoSmithKline
19.3.1 Key Facts
19.3.2 Business Overview
19.3.3 Business Segmentation
19.3.4 Business Segmentation by Revenue 2012 and 2013
19.3.5 Sales by Geography
19.3.6 Pipeline Products
19.3.7 Business Strategy
19.3.8 Key Information
19.3.9 SWOT Analysis
19.4 Novartis
19.4.1 Key Facts
19.4.2 Business Description
19.4.3 Business Segmentation
19.4.4 Revenue by Business Segmentation
19.4.5 Revenue Comparison 2012 and 2013
19.4.6 Sales by Geography
19.4.7 Business Strategy
19.4.8 Key Developments
19.4.9 SWOT Analysis
19.5 Sanofi
19.5.1 Key Facts
19.5.2 Business Description
19.5.3 Business Segmentation
19.5.4 Revenue by Business Segmentation
19.5.5 Revenue Comparison 2012 and 2013
19.5.6 Sales by Geography
19.5.7 Business Strategy
19.5.8 Key Developments
19.5.9 SWOT Analysis
20 Other Reports in this Series
List of Exhibits:
Exhibit 1: Market Research Methodology
Exhibit 2: Pathophysiology of HER-2 Positive Breast Cancer
Exhibit 3: Prevalence of HER-2 Positive Breast Cancer in US 2014
Exhibit 4: Prevalence of HER-2 Positive Breast Cancer in US 2014 (in percentage)
Exhibit 5: IHC: Diagnosis of HER-2 Positive Breast Cancer
Exhibit 6: FISH: Diagnosis of HER-2 Positive Breast Cancer
Exhibit 7: Management of HER-2 Positive Breast Cancer
Exhibit 8: ASCO Treatment Guidelines for HER-2 Positive Breast Cancer
Exhibit 9: Snapshot of Economic Burden of HER-2 Positive Breast Cancer Market in US
Exhibit 10: Snapshot of HER-2 Positive Breast Cancer Market in US 2014
Exhibit 11: HER-2 Positive Breast Cancer Market in US 2014-2019 (US$ million)
Exhibit 12: Drivers and Challenges of HER-2 Positive Breast Cancer Market in US
Exhibit 13: Segmentation of HER-2 Positive Breast Cancer Market in US by Type of Therapy
Exhibit 14: Segmentation of HER-2 Positive Breast Cancer Market in US by Type of Therapy 2014
Exhibit 15: Segmentation of HER-2 Positive Breast Cancer Market in US by Molecule Type
Exhibit 16: Segmentation of HER-2 Positive Breast Cancer Market in US by Molecule Type 2014
Exhibit 17: Segmentation of HER-2 Positive Breast Cancer Market in US by Route of Administration
Exhibit 18: Segmentation of HER-2 Positive Breast Cancer Market in US by Route of Administration 2014
Exhibit 19: Buying Criteria of HER-2 Positive Breast Cancer Market in US
Exhibit 20: Drivers and their Impact on Key Customer Category of HER-2 Positive Breast Cancer Market in US
Exhibit 21: Five-year Survival Rate by Stage of Diagnosis (SEER Analysis for 2004-2010)
Exhibit 22: Revenue Comparison of Top Drugs for HER-2 Positive Breast Cancer 2013 (US$ million)
Exhibit 23: Celgene: Product Portfolio
Exhibit 24: Abraxane: YoY Growth Rate and Global Revenue 2010-2013 (US$ million)
Exhibit 25: F. Hoffmann-La Roche: Product Portfolio
Exhibit 26: Herceptin: YoY Growth Rate and Revenue 2010-2013 (US$ million)
Exhibit 27: Perjeta: Revenue 2012 and 2013 (US$ million)
Exhibit 28: Xeloda: YoY Growth Rate and Revenue 2010-2013 (US$ million)
Exhibit 29: GlaxoSmithKline: Product Portfolio
Exhibit 30: Tykerb: YoY Growth Rate and Revenue 2010-2013 (US$ million)
Exhibit 31: Novartis: Product Portfolio
Exhibit 32: Femara: YoY Growth Rate and Revenue 2010-2013 (US$ million)
Exhibit 33: Sanofi: Product Portfolio
Exhibit 34: Taxotere: YoY Growth Rate and Global Revenue 2010-2013 (US$ million)
Exhibit 35: Celgene: Business Segmentation by Revenue 2011-2013 (US$ million)
Exhibit 36: Celgene: Sales by Geography 2013
Exhibit 37: Business Segmentation of F. Hoffmann-La Roche Ltd. 2013
Exhibit 38: F. Hoffmann-La Roche Ltd.: Business Segmentation by Revenue 2012 and 2013
Exhibit 39: F. Hoffmann-La Roche Ltd.: Sales by Geography 2013 (Pharmaceuticals Division)
Exhibit 40: F. Hoffmann-La Roche Ltd.: Sales by Geography 2013 (Diagnostics Division)
Exhibit 41: GlaxoSmithKline: Business Segmentation 2013
Exhibit 42: GlaxoSmithKline: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 43: GlaxoSmithKline: Sales by Geography 2013
Exhibit 44: GlaxoSmithKline: Pipeline Products 2013
Exhibit 45: Novartis AG: Business Segmentation
Exhibit 46: Novartis AG: Revenue by Business Segmentation 2013
Exhibit 47: Novartis AG: Revenue by Business Segmentation 2012 and 2013 (US$ million)
Exhibit 48: Novartis AG: Revenue by Geographical Segmentation 2013
Exhibit 49: Sanofi SA: Business Segmentation
Exhibit 50: Sanofi SA: Revenue by Business Segmentation 2013
Exhibit 51: Sanofi SA: Revenue by Business Segmentation 2012 and 2013 (US$ million)
Exhibit 52: Sanofi SA: Sales Revenue by Geographical Segmentation 2013
